Defence Orders Accelerating — Can Revenue Growth Sustain as Fundraise Recalibrates
Balu Forge enters Q2 on the back of a 29% revenue surge in Q1 FY27, driven by artillery shell dispatch momentum and new defence/aerospace orders. The Street expects the company to sustain momentum despite FII selling and near-term fundraise dilution, with consensus targeting ₹730 (38% upside). Watch margin sustainability and the pace of order execution as the company scales production.
What to Expect
~₹310–330 Cr
Pace Q1 momentum (+29% YoY); defence order execution & aerospace backlog.
~₹68–72 Cr
Margins ~21–22% — assume cost absorption for new defence line ramp, offset by higher-margin aerospace orders.
EBITDA ~₹110–120 Cr
Swing factor: pricing power on artillery shells vs. raw-material headwinds; capex drag from ring-rolling line commissioning.
Strong print: Revenue >₹330 Cr, PAT >₹72 Cr. Signals defence order pipeline filling faster than expected, aerospace revenue ramp-up, and margin resilience despite capex cycle. Weak print: Revenue <₹310 Cr, PAT <₹68 Cr. Suggests slowing defence execution, margin pressure from raw-material cost increases, or delays in new contract shipments.
Is the Company On Track?
Yes, on trajectory. Q1 FY27 delivered 29% revenue growth and 16% PAT growth — both outpacing FY26's full-year baseline (20% revenue, 27% PAT). The defence order funnel is live: 152mm shell dispatches underway, 155mm ERFB quality approval secured, and new Czech/US/Indian government contracts signed. Full-year FY27 guidance remains unannounced, but prior commentary suggested operating leverage in H2 as defence volume compounds. The ring-rolling acquisition (Sept 2026) adds large-forging capability for NATO-supply-chain work — a medium-term margin and scale driver. Watch: whether the company raises full-year revenue guidance on or after results.
What the Street Says
Since Last Quarter — What Moved
Aug 12
$60M FCCB issuance approved (Board)
Fundraise momentum; dilution ~4–5% pre-conversion
Aug 17
155mm ERFB artillery shell contract announced
Defence order visibility +; gross margin pressure if commodity-priced
Sep 3
Ring rolling production line acquisition (OD 6.7m)
Capex spike H2 FY27; unlocks large-forging/NATO work
Sep 4
EGM approves FCCB fund-raise (shareholder vote)
Deal progress; FII voting participation fell vs prior years
Nov 2
Defence/aerospace update: 152mm dispatches live, new global clients
Operational momentum; no quantified order value disclosed
Nov 6
Board Meeting agenda: results + preferential issue approval
Second fundraise tranche (equity, lower dilution than FCCB)
Ownership shift: FII ownership fell 98bps QoQ (5.04% in Q1 FY27 vs 6.02% in Q4 FY26). Bulk deals in Aug 2026 show churning around ₹617–622 range — positioning ahead of fundraise? Promoter stake stable ~53.5%. DII inching up (+6bps to 0.95%) suggests domestic accumulation. Fundraise context: The $60M FCCB (convertible, 3–5% dilution at 20% premium) and pending preferential issue signal capex-heavy expansion phase. Without full-year guidance, it's unclear if net capex (fundraise net of cash generation) points to FY28 margin upside or refinancing risk.
What to Watch on Result Day
1 · Revenue run-rate & order backlog disclosure
Does Q2 sustain Q1's 29% YoY growth or moderate to 18–22%? Management must signal full-year FY27 revenue guidance and quantify defence/aerospace order book in hand. Anything <15% YoY growth signals demand slowdown.
2 · Operating margin — hold or expand?
Q1 EBITDA margin ~36%. Watch for raw-material headwinds (steel, scrap) and labour/energy inflation. Artillery shell orders typically lower-margin than aerospace work. If Q2 EBITDA margin <34%, margin expansion thesis is at risk.
3 · Capex plan & fundraise use
Management must clarify ring-rolling capex quantum, timeline to commissioning, and expected revenue contribution in FY28. Capex >50 Cr suggests earnings dilution through FY27; <30 Cr suggests conservative balance-sheet posture.
4 · Fundraise timing & FII dilution
When will FCCB issuance close? Will preferential allotment exclude FII (protecting existing FII %) or dilute further? If FII stake falls below 5%, institutional ownership dips into penny-stock territory — likely drag on valuation.
5 · Debt/leverage post-fundraise
Net debt post-FCCB & preferential issue. If net debt/EBITDA >1.5x (after fundraise), concern about covenant headroom and refinance risk in a rate-tightening cycle.
Balu Forge enters Q2 FY27 with strong operational momentum — defence orders flowing, new capacity coming online, and analyst targets implying 38% upside. The challenge: execution amid a capital cycle (fundraise, acquisitions) and macro headwinds (FII selling, input costs). A strong Q2 print (revenue >₹330 Cr, margins 21%+) resets the narrative to earnings growth and de-risks the ₹730 consensus target. A miss (revenue <₹310 Cr, margins <20%) will trigger a reset on the defence order backlog depth and full-year guidance, likely pressuring the stock into Q3.
The three things to watch: (1) Revenue growth sustains above 25% YoY despite increased defence order volume (typically lower-margin); (2) EBITDA margin holds above 34% — a critical psychological level for ₹700+ valuations; (3) Management clarifies use of $60M FCCB + preferential issue capital and re-guides FY27 operating leverage without taking on excess leverage.
Balu Forge Q2: Consol PAT +18% YoY to ₹76.6 Cr, Margins Expand as Revenue Growth Cools
PAT +17.76% YoY · revenue +8.29% · margins expanding
₹324.34 Cr
+8.29% YoY
₹76.59 Cr
+17.76% YoY
23.19%
+1.7pp YoY
₹6.59
Balu Forge's consolidated PAT rose 17.8% YoY to ₹76.59 Cr (from ₹65.04 Cr) and 15.9% QoQ (from ₹66.09 Cr), on revenue of ₹324.34 Cr, up 8.3% YoY and 7.9% QoQ. The print beat our pre-result range on profit (we expected PAT ₹68-72 Cr) and landed within band on revenue (we expected ₹310-330 Cr); no formal Street consensus could be located for this specific quarter via web search — coverage is thin (5-7 analysts per our pre-result preview) and no Q2-specific preview turned up — so the comparison here is against our own expectation band rather than a published consensus number. Consolidated EPS was ₹6.59 versus ₹6.08 a year ago and ₹5.49 in Q1 FY27.
Q2 FY-2027 vs prior quarters
Margins expanded on both measures: net margin (PAT/total income) rose to 23.2% from 21.5% YoY (21.7% QoQ), and operating margin (revenue less materials, employee and other opex, excluding finance cost and depreciation) rose to 28.9% of revenue from about 27.7% YoY (28.2% QoQ) — resolving the pre-result watch item on margin sustainability in the company's favour. The group-level 8.3% YoY revenue growth is a sharp deceleration from the ~29% YoY surge flagged for Q1 FY27, but this is a consolidation effect rather than core-business weakness: standalone (India) revenue grew 14.8% YoY to ₹195.44 Cr and standalone PAT grew 32.8% YoY to ₹47.26 Cr, while Safa Otomotiz FZE-LLC contributed ₹128.98 Cr revenue and ₹32.71 Cr PAT this quarter — almost unchanged from roughly ₹129.3 Cr a year ago. There were no exceptional items in either base this quarter or last year, so both YoY comparisons are on a clean, like-for-like basis.
The stock went into the print at ₹550.3, up 13.1% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.
The same board meeting approved a ₹162 Cr preferential allotment of 30 lakh warrants to promoters Trimaan and Jaikaran Chandock at ₹540/warrant (a premium issue priced above the ICDR floor), alongside raising authorised share capital from ₹125 Cr to ₹132 Cr — both subject to shareholder approval at an EOGM called for December 12, 2026. This follows the quarter's business update on new defence-order execution and global client wins (November 2, 2026) noted in our event records. Management has no formal guidance or concall commentary on record for this quarter, and no press release was available to cross-check the company's own framing of the print — both are noted gaps rather than silent omissions.
W1
Safa Otomotiz FZE-LLC contributed ₹128.98 Cr revenue/₹32.71 Cr PAT this quarter, flat vs ~₹129.3 Cr a year ago — watch whether this segment reaccelerates or keeps diluting group growth
W2
₹162 Cr promoter warrant issue (30 lakh warrants at ₹540/warrant) pending EOGM approval on Dec 12, 2026 — watch final dilution impact and stated use of proceeds
W3
Operating margin run-rate at 28.9% of revenue (up from 28.2% QoQ, 27.7% YoY) — watch if this holds as defence-order execution scales